Japanese Encephalitis (JE)
Vaccines Forecast
Japanese encephalitis (JE) virus is an enzootic, mosquito-borne flavivirus in which humans are incidental "dead end" hosts, infected but unable to pass the virus on. It remains a severe paediatric disease across endemic South East Asia and the Western Pacific, where around 3 billion people live at risk and children under 15 carry the heaviest burden of encephalitis, death and lifelong neuropsychiatric sequelae. Decades-old vaccines, IXIARO, IMOJEV and the Chinese live-attenuated SA 14-14-2, now sit alongside a steadily expanding GAVI rollout and, most strikingly, JE virus's confirmed establishment on mainland Australia since 2022, a genuine geographic expansion of the disease. This is a comprehensive endemic and travel-market commercial assessment to 2030, drawing on VacZine Analytics' long standing, independent authority in travel disease vaccine markets.
- Format
- Executive presentation + Excel model
- Coverage
- Endemic and travel markets
- Indications
- JE prevention, routine, catch-up & travel
- Forecast horizon
- To 2030
- Approach
- Value ($m)/volume (mio doses) demand model, all age segments incl. catch-up
- Base edition
- Jan 2017 edition
- Availability
- Syndicated / bespoke
countries in SE Asia & W. Pacific
overwhelmingly in children
neuropsychiatric sequelae
circulation on mainland Australia
A decades-old paediatric killer whose map is still being redrawn
This review sets out JE virology and its zoonotic transmission cycle, the disease's severe paediatric clinical picture, and the latest epidemiological evidence, including its confirmed spread into a wholly new geography.
Pathogen overview - Japanese encephalitis virus (JEV)
Japanese encephalitis virus (JEV) is a flavivirus in the same family as West Nile, St Louis encephalitis and dengue viruses. It circulates in an enzootic cycle between Culex mosquitoes, principally Culex tritaeniorhynchus, and amplifying vertebrate hosts, chiefly domestic pigs and wading ardeid birds such as herons and egrets, which develop high enough viraemia to infect further mosquitoes. Humans, along with horses, are incidental "dead end" hosts: infection can be severe, but viraemia never reaches levels sufficient to sustain further transmission back to mosquitoes. Most human infections are mild or entirely asymptomatic, with only a small minority, commonly cited at around 1 in 250 to 1 in 1,000 infections, progressing to clinically apparent encephalitis, but that minority carries a heavy toll.
JE remains overwhelmingly a disease of childhood in endemic countries. Around 3 billion people live at risk across 24 countries of South East Asia and the Western Pacific, and because most adults in long-endemic areas acquired natural immunity through childhood exposure, symptomatic disease and death concentrate heavily in children under 15 in poor rural, agricultural areas where pig-rearing, rice paddy irrigation and mosquito breeding sites sit close to human dwellings. Estimates of annual burden vary by methodology and have been revised over time; WHO and CDC modelling place the toll at up to an estimated 20,000 deaths a year, with a case-fatality rate of roughly 20 to 30% among those with encephalitis. Among survivors, around 30% are left with permanent neuropsychiatric or motor sequelae, ranging from cognitive and behavioural impairment to seizure disorders and paralysis. There is no specific antiviral treatment; care is entirely supportive, which is exactly why vaccination, not post-exposure treatment, has always sat at the centre of JE control policy.
Vaccines against JE have been available for decades and used in large-scale routine immunisation programmes in Japan, South Korea and China, alongside newer inactivated vero-cell derived vaccines now used more widely across endemic Asia. But the disease's geography is no longer static. JE virus emerged in sustained circulation on mainland Australia for the first time in 2022, a well-documented, genuinely new range expansion linked to a distinct viral genotype and favourable La Nina-driven mosquito conditions, causing over 40 confirmed human cases and several deaths and infecting piggeries across Queensland, New South Wales, Victoria and South Australia. Detections fell away in 2023 but resurged in the 2024/25 summer with further human cases, deaths and infected pig farms, and mosquito surveillance in the 2025/26 season has again detected the virus, earlier than in any previous year. Australian public health authorities now regard JEV as effectively endemic to the Australian mainland, a structural addition to the traditional endemic map that any contemporary JE vaccine demand model needs to account for.
An established, decades-deep field still being reshaped by GAVI and geography
The JE vaccine market has matured over decades from older mouse brain-derived vaccines to today's live-attenuated and vero-cell inactivated options. What is changing now is reach: GAVI-supported introduction into new endemic countries, and a genuinely new endemic geography in Australia.
-
ValnevaLicensed, travel & endemic marketsIXIARO Inactivated, vero cell-derived
IXIARO remains the principal Western travel vaccine for JE and the only JE vaccine approved for use in the United States, where it is licensed from 2 months of age. It also holds approvals across Canada and Europe. Valneva continues to supply IXIARO under long-term government contracts, including a US Department of Defense supply agreement worth a minimum of $32.8 million confirmed in January 2025. -
SanofiLicensed, Asia-PacificIMOJEV Live-attenuated, chimeric yellow fever/JE backbone
IMOJEV is a single-dose, live-attenuated chimeric vaccine built on the 17D yellow fever vaccine backbone with JE surface genes, licensed from 12 months of age. It remains marketed across Australia, Cambodia, Hong Kong, Indonesia, Malaysia, the Philippines, Singapore, South Korea, Sri Lanka, Taiwan, Thailand and Vietnam, with its Australian import and supply consent renewed through to mid-2026. -
Chengdu Institute of Biological Products (CNBG)WHO-prequalified, GAVI workhorseSA 14-14-2 Live-attenuated
First prequalified by WHO in 2013, the first Chinese-manufactured vaccine to achieve WHO prequalification, SA 14-14-2 remains the principal vaccine behind GAVI-supported JE introduction and catch-up campaigns. By end 2023, more than 7.8 million children had been reached through GAVI-supported routine immunisation and over 17.7 million more through catch-up campaigns. -
Regional manufacturers, India & AsiaLicensed, local marketsVero-cell derived inactivated vaccines
Locally manufactured inactivated, vero-cell derived JE vaccines continue to supply domestic immunisation needs in India and other endemic Asian markets, supplementing the live-attenuated options above and broadening the competitive base this report's model draws upon. In April 2026, Japan's KM Biologics (a Meiji Seika Pharma subsidiary) signed a technology collaboration with the Serum Institute of India (SII) to develop and manufacture its vero-cell derived JE vaccine in India; Meiji confirmed in August 2026, following a meeting between its president and India's Commerce and Industry Minister, that SII is expected to file for Indian regulatory approval as early as 2027, targeting domestic paediatric supply. -
GAVI, the Vaccine AllianceProgramme rollout, ongoingGAVI JE vaccine support programme
Since the programme began in 2015, GAVI has supported five countries, Lao PDR, Nepal, Myanmar, Cambodia and Indonesia, to run JE vaccination campaigns and introduce the vaccine into routine immunisation. Bangladesh is next, with provisional GAVI support secured and a sub-national introduction campaign planned for 2026.
IXIARO, IMOJEV and SA 14-14-2 have between them defined the JE vaccine market for over a decade, but the addressable footprint around them keeps growing. GAVI's steady, country-by-country introduction programme continues to add routine and catch-up demand across endemic Asia, with Bangladesh next in line for 2026, while JE virus's confirmed, now-recurring establishment on mainland Australia since 2022 has opened a genuinely new geography that sits outside the traditional endemic map altogether. The VacZine Analytics model quantifies the commercial opportunity this combination creates across endemic and travel markets to 2030.
Six analytical layers - one commercial picture
This is a genuinely comprehensive report spanning disease burden, the established vaccine competitive landscape, GAVI introduction tracking and scenario-based demand forecasting across endemic and travel markets to 2030.
Value ($m) and volume (mio doses) demand modelling to 2030 across endemic countries and travel/traveler markets, all age segments.
Full review of IXIARO, IMOJEV, SA 14-14-2 and regional vero-cell inactivated vaccines across their respective markets.
Ideal target product profile assessment across routine infant, paediatric catch-up and adult traveler segments.
Country-by-country tracking of GAVI-supported campaigns and routine introduction, including Bangladesh's planned 2026 rollout.
Full global burden review, updated for the confirmed range expansion of JEV into mainland Australia since 2022.
Designed as an ideal tool to aid decision making in JE vaccine market entry, access strategy and investment planning.
A glimpse of the commercial model
The table below shows a partial view of the indication and geography framework. Full volume/value outputs, pricing assumptions and country-level data are in the licensed model.
| Indication / segment | Geography | Target group | Vaccine status | Revenue scenario |
|---|---|---|---|---|
| JE prevention - routine infant/childhood | Endemic SE Asia & W. Pacific | Paediatric (routine EPI) | Licensed (SA 14-14-2 & others) | Modelled |
| JE prevention - catch-up campaigns | GAVI-eligible endemic countries | Children under 15 (catch-up) | Licensed | Modelled |
| JE prevention - travelers | Non-endemic source markets | International travelers & expatriates | Licensed (IXIARO) | Modelled |
| ██████████ | █████ | ████ | ██████ | $██m (base) |
| ██████████ | █████ | ████ | ██████ | $██m (upside) |
| Total addressable - base | All endemic & travel geographies | All groups | All scenarios | $███m |
What you receive
A comprehensive intelligence package combining a detailed executive presentation and a fully interactive forecast model, built for organisations evaluating the JE vaccine opportunity across endemic and travel markets.
- Executive presentation (PDF) - disease background, epidemiology, vaccine landscape and full commercial assessment with supporting narrative and references
- MS-Excel value/volume forecast model - demand outputs to 2030 across all relevant countries, age segments and channels, including catch-up
- Endemic & travel-market coverage - country-level modelling across endemic South East Asia and the Western Pacific, alongside non-endemic traveler source markets
- Competitor intelligence - IXIARO (Valneva), IMOJEV (Sanofi), SA 14-14-2 (Chengdu Institute of Biological Products/CNBG) and regional vero-cell inactivated vaccines
- Updated epidemiology module - current global burden data alongside JEV's confirmed, recurring establishment on mainland Australia since 2022
- GAVI introduction tracker - country-by-country status of GAVI-supported campaigns and routine introduction, including Bangladesh's planned 2026 rollout
Built for organisations evaluating the JE vaccine opportunity
Most valuable to teams assessing the Japanese encephalitis vaccine market against their own pipeline, BD ambitions or investment thesis, drawing on VacZine Analytics' long standing expertise in travel diseases.
Vaccine developers
Positioning, target product profile and commercial feasibility assessment for existing and any future JE candidates.
Corporate strategy & BD
Validate the size and trajectory of a market being extended by GAVI introduction and a genuinely new endemic geography.
Investors & analysts
Independent assessment of market structure and commercial upside for due diligence on JE and wider travel vaccine entrants.
Public health & immunisation programmes
Demand modelling to support routine, catch-up and traveler vaccination programme planning in endemic and newly-affected regions.
Researchers & academia
Comprehensive epidemiology and vaccine landscape review to support grant, translational and public health planning.
Market access & policy
Pricing benchmarks and access-pathway assumptions across public immunisation, GAVI-supported and private traveler-health channels.
VacZine Analytics has long standing expertise in travel diseases, positioning us to track the Japanese encephalitis vaccine market's established supply side against its evolving epidemiological footprint. This is a genuinely comprehensive analysis spanning the traditional endemic belt across South East Asia and the Western Pacific, GAVI's country-by-country introduction programme, and travel markets worldwide, and it has been well received by clients in the field for the depth of its epidemiological review and its country-level demand modelling. Few groups have followed this market as closely for as long, and that recognised, independent expertise underpins everything in the analysis.
This report was last published in Jan 2017. A refresh would incorporate current WHO/CDC burden data, GAVI's continuing JE introduction programme, and the confirmed, recurring establishment of JE virus on mainland Australia since 2022, alongside the current status of IXIARO, IMOJEV and SA 14-14-2. The full syndicated MarketVIEW edition proceeds subject to sufficient client buy-in; where a faster or more tailored answer is required, VacZine Analytics can also be commissioned to deliver bespoke, ad-hoc analysis on this market.
Syndicate the refresh - or commission the answer you need
Register your interest to help shape and secure a full syndicated MarketVIEW refresh, which proceeds subject to sufficient client buy-in. Single-licence and multi-user options follow on publication. Need something faster or more specific? VacZine Analytics can be commissioned for bespoke, ad-hoc JE vaccine analysis, a briefing call is included on request.